NICOX (EPA:COX) | WebDisclosure

Basculer en Français

10816	Companies
234393	Keywords
163235	Articles
125387	Press releases

Home
Companies
NICOX

PRESS RELEASE

published on 12/16/2025 at 07:30, 7 months 25 days ago

Nicox finalise la génération des données clés de demande d’autorisation de mise sur le marché de NCX 470 pour un dépôt maintenu au premier semestre 2026
Nicox finalise la génération des données clés pour la demande d’autorisation de mise sur le marché de NCX 470, dépôt maintenu au premier semestre 2026. Réunions pré-NDA avec la FDA américaine et dépôt NDA en Chine également en bonne voie

FDA Autorisation De Mise Sur Le Marché Nicox NCX 470 Dépôt NDA
PRESS RELEASE

published on 12/16/2025 at 07:30, 7 months 25 days ago

Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026
Nicox completes key data generation for NCX 470 new drug application submission in H1 2026, including clinical trial and stability data. U.S. and China submissions on track

FDA Clinical Trials Nicox NCX 470 New Drug Application
BRIEF

published on 10/23/2025 at 07:35, 9 months 18 days ago

Nicox publie ses résultats financiers du premier semestre 2025

Résultats Financiers Ophtalmologie Remboursement De La Dette Contrôle Des Coûts NCX 470
BRIEF

published on 10/23/2025 at 07:35, 9 months 18 days ago

Nicox Releases First Half 2025 Financial Results

Financial Results Debt Repayment Ophthalmology Cost Control NCX 470
PRESS RELEASE

published on 10/23/2025 at 07:30, 9 months 18 days ago

Nicox Provides First Half 2025 Financial Results
Nicox provides first half 2025 financial results, expects NDA submissions for NCX 470 in 2026. Company aims to finance operations for 12 months and repay debts by 2026

Financial Results Debt Repayment Nicox NCX 470 NDA Submissions
BRIEF

published on 10/02/2025 at 07:35, 10 months 8 days ago

Nicox : Résultats positifs pour NCX 470 dans l'étude Denali

Essai Clinique Ophtalmologie Nicox NCX 470 Pression Intraoculaire
BRIEF

published on 10/02/2025 at 07:35, 10 months 8 days ago

Nicox: Positive results for NCX 470 in the Denali study

Clinical Trial Ophthalmology Nicox NCX 470 Intraocular Pressure
PRESS RELEASE

published on 10/02/2025 at 07:30, 10 months 8 days ago

Nicox annonce que NCX 470 a démontré une efficacité soutenue jusqu’à 12 mois dans l’essai clinique Denali, sans effets indésirables nouveaux observés
Nicox annonce que NCX 470 a démontré une efficacité soutenue jusqu’à 12 mois dans l’essai clinique Denali, sans effets indésirables nouveaux observés. Les analyses préplanifiées confirment un profil similaire à Mont Blanc

Étude Clinique Ophtalmologie Nicox NCX 470 Denali
PRESS RELEASE

published on 10/02/2025 at 07:30, 10 months 8 days ago

Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations
Nicox's NCX 470 shows sustained efficacy with no new safety concerns in Denali trial. Data presented at upcoming ophthalmology conferences

Nicox NCX 470 Denali Trial Ophthalmology Conferences Sustained Efficacy
BRIEF

published on 09/04/2025 at 07:35, 11 months 6 days ago

Nicox prévoit de rembourser sa dette grâce à l'avancement du NCX 470

Ophtalmologie Remboursement De La Dette Nicox NCX 470 Licences

Accesswire

Published on 08/10/2026 at 15:30, 2 hours 46 minutes ago

Silver Spruce Resources, Inc. Announces New Chief Financial Officer
Published on 08/10/2026 at 15:25, 2 hours 51 minutes ago

Gemdale Gold Intersects 5.19m at 14.01 g/t Au within 110m at 1.18 g/t Au at the Pontio Gold Project, Finland
Published on 08/10/2026 at 14:30, 3 hours 46 minutes ago

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
Published on 08/10/2026 at 13:30, 4 hours 46 minutes ago

Sterling Expands High-Grade Copper Mineralization East at MEPS Intersecting 203 Metres at 0.51% CuEq: Includes 16.25 Metres at 2.31% CuEq and 9.50 Metres at 2.34% CuEq within 445 Metres at 0.40% CuEq
Published on 08/10/2026 at 13:00, 5 hours 16 minutes ago

Alaska Energy Metals Announces Drilling Program for the Mcbride Prospect, Angliers-Belleterre Project, Quebec, Canada

View all ACCESSWIRE

EQS Group

Published on 08/10/2026 at 17:50, 26 minutes ago

Disclosure according to Article 5(1)(b) of the EU Regulation No. 596/2014 and Article 2(3) of the Delegated EU Regulation No. 2016/1052 - 1st Interim Report
Published on 08/10/2026 at 17:38, 38 minutes ago

PATRIZIA delivers strong earnings growth with EUR 42.7m EBITDA (+46.6% y-o-y) in H1 2026
Published on 08/10/2026 at 17:11, 1 hour 5 minutes ago

CORRECTION FROM SOURCE: North Peak Commences 2026 Drilling Campaign at Prospect Mountain, Eureka, Nevada
Published on 08/10/2026 at 16:12, 2 hours 4 minutes ago

dK Calls on PANDION AG Bondholders to Join Forces
Published on 08/10/2026 at 15:56, 2 hours 20 minutes ago

Viromed Medical AG signs distribution partnerships for ViroCAP® in six additional markets

Les Echos

Published on 08/10/2026 at 18:00, 16 minutes ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 16 minutes ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 17:45, 31 minutes ago

Weekly share buyback
Published on 08/10/2026 at 17:45, 31 minutes ago

Déclaration hebdomadaire de rachat d'actions
Published on 08/10/2026 at 11:53, 6 hours 22 minutes ago

GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026

View all LES ECHOS COMFI WIRE